Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 4/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25129589 | 0.92 | OPRM1 (0.35) | OPRL1OPRM1HRH3SIGMAR1CYP2D6 | |
| SCHEMBL25443918 | 0.87 | — | — | |
| SCHEMBL22920409 | 0.87 | OPRL1 (0.38) | OPRL1OPRM1SIGMAR1 | |
| SCHEMBL22363525 | 0.86 | OPRL1 (0.36) | OPRL1OPRM1HRH3SIGMAR1CYP2D6 | |
| SCHEMBL24250686 | 0.86 | OPRL1 (0.36) | OPRL1OPRM1HRH3SIGMAR1KDM4E | |
| SCHEMBL24942058 | 0.86 | KDM4E (0.31) | KDM4EMEN1KMT2A | |
| SCHEMBL23847242 | 0.85 | OPRM1 (0.34) | OPRL1OPRM1 | |
| SCHEMBL19426013 | 0.85 | OPRM1 (0.34) | OPRL1OPRM1 | |
| SCHEMBL408516 | 0.85 | CHRNA7 (0.34) | HRH3CYP2D6KCNH2KDM4E | |
| SCHEMBL24919016 | 0.85 | OPRM1 (0.38) | OPRL1OPRM1HRH3SIGMAR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-11767330-B2 | Citrate salt, pharmaceutical compositions, and methods of making and using the same | FOGHORN THERAPEUTICS INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230066136-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230024096-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | C4 THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20220177449-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20210017274-A1 | Drug-Conjugates With a Targeting Molecule and Two Different Drugs | SORRENTO THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177449-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | OPRL1 393/4885OPRM1 1503/4885HRH3 2107/4885 |
| US-20230066136-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | OPRL1 4479/4885OPRM1 4630/4885HRH3 2014/4885 |
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | OPRL1 4519/4885OPRM1 4702/4885HRH3 3347/4885 |
| US-11767330-B2 | Citrate salt, pharmaceutical compositions, and methods of making and using the same | CS, SMARCC2, SMARCC1 | OPRL1 4859/4885OPRM1 4873/4885HRH3 2752/4885 |
| US-20210017274-A1 | Drug-Conjugates With a Targeting Molecule and Two Different Drugs | ERBB2, ABCG2, DYNLL2 | OPRL1 969/4885OPRM1 1775/4885HRH3 2488/4885 |
| US-20230024096-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | SMARCC1, SMARCC2, SMARCA2 | OPRL1 4171/4885OPRM1 4615/4885HRH3 3573/4885 |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | OPRL1 4479/4885OPRM1 4630/4885HRH3 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.